	US 12,109,261 B1
	Stabilized hemagglutinin (HA) trimers as influenza vaccine antigens
Linling He, San Diego, CA (US); Jiang Zhu, San Diego, CA (US); Ian A. Wilson, La Jolla, CA (US); and Yi-Zong Lee, San Diego, CA (US)
Assigned to The Scripps Research Institute, La Jolla, CA (US)
Filed by THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA (US)
Filed on May 22, 2024, as Appl. No. 18/670,803.
Claims priority of provisional application 63/503,725, filed on May 23, 2023.
Int. Cl. C07K 14/005 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); C07K 1/00 (2006.01); C07K 14/11 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/145 (2013.01) [C07K 14/005 (2013.01); A61K 2039/6031 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16222 (2013.01); C12N 2760/16234 (2013.01); C12N 2760/16322 (2013.01); C12N 2760/16334 (2013.01)]

23 Claims

1. An engineered influenza viral hemagglutinin (HA) protein, comprising a modified HA2 ectodomain, wherein the modified HA2 ectodomain comprises substitution of the amino acid residue at position 95 or at position 106 with a hydrophobic residue; wherein amino acid numbering of HA2 is based on Influenza A Subtype H3.